References
1. NACO. Pediatric antiretroviral therapy (ART) guidelines. May 2014. Accessed at http://naco.gov.in/sites/default/files/Pediatric_14-03-2014.pdf
2. Srikanth B.A, Babu C, Yadav H.N, Jain S.K. Incidence of adverse drug reactions in human immunodeficiency virus positive patients using highly active antiretroviral therapy. J. Adv Pharm Technol Res. 2012; 3(1): 62-67.
3. Gil AC, Lornzetti R, Mendez GB, Morcillo AM, Toro AA ,Silva MT, et al. Sao Paulo Medical J. Hepatotoxicity in HIV- infected children and adolescents on antiretroviral therapy. Sao Paulo Med Journal.2007;125(4): 205-9.
4. WHO. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach: 2010 Revision. WHO; Geneva.
5. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:685-93.
6. Chatterjee S, Bose S S, Khuntdar B, Bhattacharya S. Are first line anti-retroviral therapies really toxic forchildren? A study from Eastern India. J AIDS HIV Res. 2012;4(9):219-222.
7. Shah I. Adverse effects of antiretroviral therapy in HIV-1 infected children. J Trop Pediatr. 2006;52(4):244-248.
8. Oumar A A, Diallo K, Dembélé J P, Samaké L, Sidibé I, Togo B, Sylla M, Tounkara A, Dao S, Tulkens P M. Adverse Drug Reactions to Antiretroviral Therapy: Prospective Study in Children in Sikasso (Mali). J PediatrPharmacolTher. 2012 Oct-Dec; 17(4): 382–388.
9. Oshikoya KA, Lawal S, Oreagba I A, Awodele O, Olayemi SO, Iroha EO, Ezeaka VC, Temiye EO, Akinsulie AO, Opanuga O, Adeyemo T, LesiF,Akanmu AS. Adverse Events in HIV- infected Children on Antiretroviral Therapy at a Teaching Hospital in Lagos, Nigeria: A Retrospective Study. Adv Pharma-coepidemiol Drug Safety. 2012. Open access journal. Accessed at https://www.omicsgroup.org/journals/adverse-events-in-hiv-infected-children-on-antiretroviral-therapy-at-a%20teaching-hospital-in-lagos-nigeria-a-retrospective-study-2167-1052.1000117.php?aid=8906#18
10. Menezes de Pádua CA, CéSAR CC, Bonolo PF, Acurcio FA, Guimaráes MDC (2006) High incidence of adverse reactions to intial antiretroviral therapy in Brazil. Braz J Med Biol Res 39: 495-505.
11. Kumar B K, Kiran G. cutaneous adverse drug reaction to antiretroviral therapy in children. Ind J PediatrDermatol. 2014;15(2):96-99.
12. Warren KJ, Boxwell DE, Kim NY, Drolet BA. Nevirapine associated Stevens-Johnson syndrome. Lancet. 1998;351:567.
13. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a non-nucleoside reverse transcripase inhibitor for the treatment of human immuno deficiency virus infection. ClinTher. 1998;20:1071–92.
14. Montaner JSG, Reiss P, Cooper D, et al. A randomized double-bind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV infected patients. The INCAS trial. JAMA 1998;279:930– 7.
15. Carr A, Cooper D. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423–30.
16. Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997; 336: 1343- 1349.
17. Rakesh L, Amit U, Kabra SK. Anti-retroviral therapy in HIV-infected children. Ind Pediatr.2005;42:789-796.
18. Hawkins T. Understanding and managing theadverse effects of antiretroviral therapy. AntivirRes. 2010;85:201-9.
19. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV cohort study, J Acquir Immune DeficSyndr , 2002;31: 50-5.
20. Pujari SN, Dravid A, Naik E, Bhagat S, Tash K, Nadler JP, Sinnott JT. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India.JAcquir Immune DeficSyndr. 2005;39(2):199-202.
21. Parakh A, Dubey AP, Kumar A, Maheshwari A.Lipodystrophy and metabolic complications of highly active antiretroviral therapy.Indian J Pediatr. 2009;76(10):1017-21. doi: 10.1007/s12098-009-0216-9.
22. Rajesh R, Vidyasagar S, Varma D M, Guddattu V, Patel N R, Varghese M, Pulagam P. Evaluating the effects of combination antiretroviral therapy regimens and the development of adverse drug reactions in Indian human immunodeficiency virus positive patients. Saudi J Health Sci. 2014;3(2):107-117.
23. Eluwa GI, Badru T, Akpoigbe K. Adverse drug reactions to antiretroviral therapy (ARVs): Incidence, type and risk factors in Nigeria. BMC ClinPharmacol 2012;12:7.
24. Lorna AR, Fatoumata D, Fla K, Karen M, Ramatoulaye D G, Edmond A et al. Anemia and Zidovudine containing Antiretroviral Therapy in Pediatric antiretroviral programmes in the IeDEA Pediatric West African Database to evaluate AIDS. J Int AIDS Soc. 2013; 16(1): 18024.
DOI: https://dx.doi.org/10.18535/jmscr/v5i5.33
